Similarly, treatment with 200 μmoles/day of sulforaphane resulted in a small (<50%) PSA decrease in patients with recurrent PCa, with a significant lengthening of the on-treatment PSA doubling time (PSADT) with respect to the pretreatment (9.6 months on-treatment vs. 6.1 months pretreatment) [305]. This evidence concerns the gene KLK3 and posterior cortical atrophy.